Literature DB >> 35612493

Contribution of G Protein-Coupled Receptor 55 to Periaqueductal Gray-Mediated Antinociception in the Inflammatory Pain.

Henry Blanton1, Sabiha Armin1, Steven Muenster1, Mary Abood2, Khalid Benamar1.   

Abstract

The brain mechanism of inflammatory pain is an understudied area of research, particularly concerning the descending pain modulatory system. The G protein-coupled receptor 55 (GPR55) is a lysophosphatidylinositol-sensitive receptor that has also been involved in cannabinoid signaling. It is widely expressed throughout the central nervous system, including the periaqueductal gray (PAG), a brainstem area and key element of the descending pain modulatory system. In this study, we used behavioral, stereotaxic injections, pharmacological tools, and two inflammatory pain models (formalin and carrageenan) to determine if GPR55 in the PAG plays a role in the pain associated with inflammation in rats. It was found that the blockade of GPR55 action in PAG can drive the descending pain modulatory system to mitigate inflammatory pain. These data show that GPR55 plays a role in the descending pain modulatory system in inflammatory pain.

Entities:  

Keywords:  GPR55; cannabinoids; descending pain modulatory system; inflammatory pain; periaqueductal gray

Mesh:

Substances:

Year:  2022        PMID: 35612493      PMCID: PMC9225399          DOI: 10.1089/can.2022.0006

Source DB:  PubMed          Journal:  Cannabis Cannabinoid Res        ISSN: 2378-8763


  21 in total

1.  Optimal scoring strategies and weights for the formalin test in rats.

Authors:  G S Watson; K J Sufka; T J Coderre
Journal:  Pain       Date:  1997-03       Impact factor: 6.961

2.  The Lysophosphatidylinositol Receptor GPR55 Modulates Pain Perception in the Periaqueductal Gray.

Authors:  Elena Deliu; Margaret Sperow; Linda Console-Bram; Rhonda L Carter; Douglas G Tilley; Daniel J Kalamarides; Lynn G Kirby; G Cristina Brailoiu; Eugen Brailoiu; Khalid Benamar; Mary E Abood
Journal:  Mol Pharmacol       Date:  2015-05-13       Impact factor: 4.436

Review 3.  Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55.

Authors:  Christopher M Henstridge; Nariman A B Balenga; Julia Kargl; Clara Andradas; Andrew J Brown; Andrew Irving; Cristina Sanchez; Maria Waldhoer
Journal:  Mol Endocrinol       Date:  2011-09-29

4.  Systems wide analyses of lipids in the brainstem during inflammatory orofacial pain - evidence of increased phospholipase A(2) activity.

Authors:  M-T Ma; J-F Yeo; G Shui; M R Wenk; W-Y Ong
Journal:  Eur J Pain       Date:  2012-01       Impact factor: 3.931

5.  Intrahypothalamic injection of deltorphin-II alters body temperature in rats.

Authors:  Khalid Benamar; Scott M Rawls; Ellen B Geller; Martin W Adler
Journal:  Brain Res       Date:  2004-09-03       Impact factor: 3.252

6.  Elevated level of the proinflammatory chemokine, RANTES/CCL5, in the periaqueductal grey causes hyperalgesia in rats.

Authors:  Khalid Benamar; Ellen B Geller; Martin W Adler
Journal:  Eur J Pharmacol       Date:  2008-07-11       Impact factor: 4.432

Review 7.  GPR55 - a putative "type 3" cannabinoid receptor in inflammation.

Authors:  Hyewon Yang; Juan Zhou; Christian Lehmann
Journal:  J Basic Clin Physiol Pharmacol       Date:  2016-05-01

8.  GPR55 in the brain and chronic neuropathic pain.

Authors:  Sabiha Armin; Steven Muenster; Mary Abood; Khalid Benamar
Journal:  Behav Brain Res       Date:  2021-03-18       Impact factor: 3.332

9.  Inflammatory and Neuropathic Nociception is Preserved in GPR55 Knockout Mice.

Authors:  Lawrence M Carey; Tannia Gutierrez; Liting Deng; Wan-Hung Lee; Ken Mackie; Andrea G Hohmann
Journal:  Sci Rep       Date:  2017-04-20       Impact factor: 4.379

10.  Effects of inflammatory pain on CB1 receptor in the midbrain periaqueductal gray.

Authors:  Adrianne R Wilson-Poe; Beth Wiese; Cherkaouia Kibaly; Lindsay Lueptow; Jeniffer Garcia; Preeti Anand; Catherine Cahill; Jose A Morón
Journal:  Pain Rep       Date:  2021-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.